EORTC has a strong track record in initiating and conducting clinical trials across thoracic cancers. The focus is not only lung cancer but also mesothelioma and thymomas. This follows EORTC strategy to challenge, re-define and develop standards of care for loco-regional as well as for systemic treatments.
Scientific projects are designed and conducted to integrate disciplines such as imaging, translational research, quality of life and quality assurance. There are multiple partnerships, especially with national groups in Europe but also with international umbrella organisations. The group places special emphasis on recruiting and mentoring junior colleagues who are interested in pursuing an academic career in the field of thoracic oncology.
Projects testing the place of immunotherapy in the treatment of lung cancer are also ongoing such as addressing the role of immunotherapy in the adjuvant setting of lung cancer.
Related NewsAll news
Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomized phase II study of the EORTC Lung Cancer Group
EORTC randomized phase II study of pleurectomy/ decortication (P/D) preceded or followed by chemotherapy in patients with early stage malignant pleural mesothelioma
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy
A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy.
EORTC has contributed to changing the standards of care for thoracic oncology:
- 1459: Exploratory analysis of the pleural mesothelioma genome by next generation sequencing
- 1495: Update of OS in 08092 and CRP marker
- 1496: Survey on Thymoma / thymic malignancy
- 1549: Pharmacogenetic analysis from the double blind randomized phase III study ofmaintenance pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung Group study
- 1557 Predict therapy in NSCLC: Studying changes in the expression of genes related to the metabolism and the chemotherapeutic activity in primary tumor and lymph and mediastinal lymph nodes infiltrated in resectable NSCLC
- 1638: Phase II, Parallel-Arm Study of MGCD265 in patients with locally advanced or metastatic NSCLC with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
IMI CANCER-ID – Cancer treatment and monitoring through identification of circulating tumor cells and tumor related nucleic acids in blood. EORTC is contributing with biological material and related data from EORTC study 1335 SPECTAlung.
European Reference Networks (ERN) for rare solid tumours (EURACAN). EURACAN is involving references centers in Europe covering ten types of rare cancers. EURACAN will improve patient cares and facilitate research in rare cancers. EORTC is providing the clinical research infrastructure. (No website available yet)
Gustave Roussy Cancer Campus
Academisch Ziekenhuis Maastricht
Institut Jules Bordet
C. Faivre-Finn - Manchester, GB
Early stage NSCLC & Radiotherapy
The Christie NHS Foundation Trust
J. Edwards - Sheffield , GB
Early stage NSCLC & Surgery
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital
M. Reck - Grosshansdorf, DE
L. Greillier - Marseille, FR
Malignant Pleural Mesothelioma
Assistance Publique - Hopitaux de Marseille - Hopital Nord
S. Lantuejoul - Grenoble, FR
Pathology & TR
CHU de Grenoble - Departement d'Anatomie et Cytologie Pathologiques
S. Novello - Orbassano, IT
Ospedale S. Luigi Gonzaga - Universita Di Torino
N. Girard - Paris, FR
M. O'Brien - Sutton, GB
Royal Marsden Hospital
L. Hendriks - Maastricht, NL
Young investigator lead
Academisch Ziekenhuis Maastricht
A. Levy - Villejuif, FR
Young investigator secretary
Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy
Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey
APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. EORTC 1613
Trial in progress: EORTC Trial 1416 A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS). Poster Presentation at the ELCC Meeting, Geneva, Switzerland, 5 - 8 May 2017.
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial